Arecor Therapeutics (LON:AREC) Issues Quarterly Earnings Results

Arecor Therapeutics (LON:AREC) announced its quarterly earnings data on Thursday. The company reported GBX (8) earnings per share (EPS) for the quarter, Digital Look Earnings reports. Arecor Therapeutics had a net margin of 38.74% and a return on equity of 14.26%.

Arecor Therapeutics Price Performance

Shares of AREC stock opened at GBX 70.31 on Friday. Arecor Therapeutics has a 1-year low of GBX 56 and a 1-year high of GBX 95. The company has a market cap of £26.55 million, a P/E ratio of 35.16 and a beta of -0.18. The company has a debt-to-equity ratio of 1.52, a current ratio of 4.35 and a quick ratio of 6.24. The stock’s 50-day moving average is GBX 71.87 and its 200 day moving average is GBX 67.97.

About Arecor Therapeutics

Arecor Therapeutics plc (AIM: AREC) is a clinical-stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases.

Lead product, AT278, is the only ultra-concentrated (500U/mL) ultra-rapid-acting insulin in development. Arecor has signed an initial strategic partnership with Sequel Med Tech, a leading automated insulin delivery (AID) system company to co-develop AT278 in combination with Sequel’s twiist™ AID system.